Overview
Hanseo Dynamics Co., Ltd. is at the forefront of biotech innovation in South Korea, dedicated to developing cutting-edge genetic therapies aimed at addressing rare and difficult-to-treat diseases. Our primary product, GenetiCore, is an advanced platform that employs CRISPR technology to create tailored therapies for patients. We have successfully conducted initial trials, demonstrating promising efficacy and safety results, and are now poised to enter the next phase of development. The funds we seek will enable us to expand our research capabilities, initiate larger clinical trials, and enhance our product pipeline. In the years leading up to 2026, we have built a strong foundation, establishing partnerships with leading research institutions and gaining recognition at prominent biotech conferences. Our team, comprised of industry experts and seasoned researchers, has experience in both biotech and pharmaceuticals, providing us a competitive edge in navigating the complexities of drug development. With the demand for personalized medicine rising, our solutions are timely and necessary, making it an opportune moment for investment. We are looking to raise $285,000, which will be piv…
Use of funds
The investment will be allocated as follows: 50% for conducting larger-scale clinical trials, 30% for R&D to expand product pipeline, and 20% for operational costs including hiring additional scientific staff and regulatory compliance.
Open case
Open this case to get the detailed business plan and direct contact with the founder or seeker.